CD40LG and autoimmune disease: Besides, in vivo study, CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications, nevertheless retain pharmacological activity and support the investigation of CDP7657 as a potential therapy for SLEs and other autoimmune diseases [239].